Opko Health, Inc. (OPK) Earnings Call Analysis

NASDAQ · Healthcare · Diagnostics & Research

13/25

Growth 4 Margin 2 Expansion 3 Platform 1 Financial 3

latest quarter score

Earnings Reports

13
OPK Q2 2026: Operating Loss Narrows $53M as Diagnostics Restructuring and Pipeline Execution Take Hold
July 28, 2026
14
OPK Q1 2026: Regeneron Milestone Potential Tops $1B as MODX Pipeline Advances
April 29, 2026
12
OPK Q4 2025: $1B+ Regeneron Milestone Upside, Diagnostics Refocus Drives Margin Reset
February 27, 2026
15
OPK Q3 2025: $192M Oncology Asset Sale Reshapes Diagnostics, Fuels R&D and Buybacks
October 29, 2025
13
Opko Health (OPK) Q2 2025: Oncology Asset Sale Unlocks $225M, Refocuses Diagnostics for Profitability
July 31, 2025
8
OPK Q1 2025: $225M LabCorp Divestment Reshapes Diagnostics, Refocuses Pipeline
July 04, 2025
OPKO Health (OPK) Q4 2024: $51 Million BARDA Boost Advances Multispecific Antibody Pipeline
February 27, 2025

Browse all companies